BR0307627A - Métodos e composições para o tratamento de doenças do olho - Google Patents

Métodos e composições para o tratamento de doenças do olho

Info

Publication number
BR0307627A
BR0307627A BR0307627-0A BR0307627A BR0307627A BR 0307627 A BR0307627 A BR 0307627A BR 0307627 A BR0307627 A BR 0307627A BR 0307627 A BR0307627 A BR 0307627A
Authority
BR
Brazil
Prior art keywords
compositions
methods
eye diseases
treating eye
eye
Prior art date
Application number
BR0307627-0A
Other languages
English (en)
Inventor
Hans-Markus Bender
Ulrich Lang
Mathias Wiesner
Martin Frieldlander
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR0307627A publication Critical patent/BR0307627A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

"MéTODOS E COMPOSIçõES PARA O TRATAMENTO DE DOENçAS DO OLHO". A presente invenção refere-se a métodos e composições destinados à profilaxia e/ou tratamento de doenças do olho, usando antagonistas de receptores de integrina <244>~ v~<225>~ 3~ e/ou <244>~ v~<225>~ 5~. As composições podem ser nanopartículas e são administradas ao olho mediante injeção dentro do subespaço de Tenon do olho.
BR0307627-0A 2002-02-14 2003-02-12 Métodos e composições para o tratamento de doenças do olho BR0307627A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02003432 2002-02-14
PCT/EP2003/001369 WO2003068253A1 (en) 2002-02-14 2003-02-12 Methods and compositions for the treatment of eye diseases

Publications (1)

Publication Number Publication Date
BR0307627A true BR0307627A (pt) 2005-01-11

Family

ID=27675621

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307627-0A BR0307627A (pt) 2002-02-14 2003-02-12 Métodos e composições para o tratamento de doenças do olho

Country Status (13)

Country Link
US (1) US20050085415A1 (pt)
EP (1) EP1474162A1 (pt)
JP (1) JP2005517038A (pt)
KR (1) KR20040091002A (pt)
CN (1) CN1658894A (pt)
AU (1) AU2003208833A1 (pt)
BR (1) BR0307627A (pt)
CA (1) CA2476120A1 (pt)
MX (1) MXPA04007770A (pt)
PL (1) PL371281A1 (pt)
RU (1) RU2004127577A (pt)
WO (1) WO2003068253A1 (pt)
ZA (1) ZA200407335B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2536185C (en) * 2003-08-20 2012-06-26 Santen Pharmaceutical Co., Ltd. Drug delivery system by administrating fine particles to sub-tenon
JP4912881B2 (ja) * 2003-10-01 2012-04-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗線維症薬としてのαｖβ３及びαｖβ６インテグリンアンタゴニスト
WO2006003519A2 (en) * 2004-07-02 2006-01-12 Novagali Pharma Sa Use of emulsions for intra: and periocular injection
CN101120002A (zh) 2005-02-17 2008-02-06 惠氏公司 环烷基稠合的吲哚、苯并噻吩、苯并呋喃和茚衍生物
JP2006257080A (ja) * 2005-02-18 2006-09-28 Santen Pharmaceut Co Ltd ステロイド化合物の副作用軽減または回避方法
WO2008054341A2 (en) * 2005-06-20 2008-05-08 The Research Foundation Of State University Of New York Method of bioimaging using nanocrystals of fluorescent dyes
KR101634983B1 (ko) * 2008-01-07 2016-07-01 살루타리스 메디컬 디바이스즈, 인코퍼레이티드 눈의 후부에 대한 방사선의 전달을 위한 외안의 최소한의 수술 방법 및 장치
US10022558B1 (en) 2008-01-07 2018-07-17 Salutaris Medical Devices, Inc. Methods and devices for minimally-invasive delivery of radiation to the eye
US9056201B1 (en) * 2008-01-07 2015-06-16 Salutaris Medical Devices, Inc. Methods and devices for minimally-invasive delivery of radiation to the eye
US9873001B2 (en) 2008-01-07 2018-01-23 Salutaris Medical Devices, Inc. Methods and devices for minimally-invasive delivery of radiation to the eye
US8608632B1 (en) * 2009-07-03 2013-12-17 Salutaris Medical Devices, Inc. Methods and devices for minimally-invasive extraocular delivery of radiation and/or pharmaceutics to the posterior portion of the eye
AU2009291747B2 (en) * 2008-09-10 2016-05-26 Genentech, Inc. Methods for inhibiting ocular angiogenesis
RU2635185C2 (ru) * 2013-12-17 2017-11-09 Иван Дмитриевич Захаров Фармацевтический препарат для профилактики и лечения прогрессирующей близорукости
USD814638S1 (en) 2016-05-11 2018-04-03 Salutaris Medical Devices, Inc. Brachytherapy device
USD815285S1 (en) 2016-05-11 2018-04-10 Salutaris Medical Devices, Inc. Brachytherapy device
USD814637S1 (en) 2016-05-11 2018-04-03 Salutaris Medical Devices, Inc. Brachytherapy device
USD808529S1 (en) 2016-08-31 2018-01-23 Salutaris Medical Devices, Inc. Holder for a brachytherapy device
USD808528S1 (en) 2016-08-31 2018-01-23 Salutaris Medical Devices, Inc. Holder for a brachytherapy device

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904649A (en) * 1986-05-23 1990-02-27 New England Medical Center Hospitals, Inc. Method and solution for treating glaucoma
US5294604A (en) * 1989-12-20 1994-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating ocular diseases by periocular administration of cyclosporine A or G
FR2678168B1 (fr) * 1991-06-28 1993-09-03 Rhone Poulenc Rorer Sa Nanoparticules ayant un temps de capture par le dysteme reticulo endothelial allonge.
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
NZ283658A (en) * 1994-04-04 1999-09-29 William R Freeman Compositions and treatment of increased intraocular pressure with phosphonyl-alkyloxy-pyrimidines/purines (nucleosides)
US5972326A (en) * 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
DE19705450A1 (de) * 1997-02-13 1998-08-20 Merck Patent Gmbh Bicyclische aromatische Aminosäuren
US5980929A (en) * 1998-03-13 1999-11-09 Johns Hopkins University, School Of Medicine Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation
DE19850131A1 (de) * 1998-10-30 2000-05-04 Merck Patent Gmbh Chromenon- und Chromanonderivate
ES2240180T3 (es) * 1999-10-21 2005-10-16 Alcon Inc. Administracion sub-tenon de medicamentos.
DE10006139A1 (de) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate
DK1381382T3 (da) * 2000-11-01 2009-02-02 Merck Patent Gmbh Fremgangsmåder og præparater til behandling af öjensygdomme

Also Published As

Publication number Publication date
KR20040091002A (ko) 2004-10-27
US20050085415A1 (en) 2005-04-21
MXPA04007770A (es) 2004-10-15
PL371281A1 (en) 2005-06-13
JP2005517038A (ja) 2005-06-09
RU2004127577A (ru) 2005-05-27
CA2476120A1 (en) 2003-08-21
EP1474162A1 (en) 2004-11-10
ZA200407335B (en) 2005-09-28
AU2003208833A1 (en) 2003-09-04
WO2003068253A1 (en) 2003-08-21
CN1658894A (zh) 2005-08-24

Similar Documents

Publication Publication Date Title
BR0211604A (pt) Inibidores de integrina para o tratamento de doenças do olho
BR0207526A (pt) Composto, composição farmacêutica, e, métodos para o tratamento da dor, da enxaqueca, depressão, ansiedade, esquizofrenia, doença de parkinson ou derrame cerebral
BRPI0512220A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
GB0223038D0 (en) Therapeutic compounds
TW200505903A (en) CGRP receptor antagonists
BRPI0512213A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
DE502005006149D1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
MXPA05002442A (es) Imidazolopiridinas y metodos para la elaboracion y uso de las mismas.
WO2007002516A3 (en) Improved dosage forms for movement disorder treatment
BRPI0412893A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de prevenção, tratamento ou melhora de doenças ou condições inflamatórias, ou doenças ou condições oftálmicas, de tratamento ou melhora de cáncer e para a produção de um composto
NZ617196A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
BR112012021337A8 (pt) formulações de apixaban.
WO2003048164A3 (en) Adenosine a2a receptor antagonists
NO20054200L (no) Pyrazoler samt fremgangsmate for fremstilling derav
WO2005072308A3 (en) Cgrp receptor antagonists
BR0309486A (pt) Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
BR0012175A (pt) Antagonistas de receptor de igiur5, seletivos para o tratamento de enxaqueca
BRPI0409523A (pt) método para o tratamento da dor neuropática, método de identificação de um composto e composição farmacêutica
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
WO2007146349A3 (en) Cgrp receptor antagonists
WO2005016883A3 (en) Acrylamide derivatives as vla-1 integrin antagonists and uses thereof
BR0115077A (pt) Métodos e composições para o tratamento de doenças dos olhos
WO2007046867A3 (en) Piperidine derivatives and their uses as therapeutic agents

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE 6A., E 7A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010.